CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


azithromycinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2843 hydroxychloroquine placebo Wiki 1.00
drug2840 hydroxychloroquine Wiki 0.50

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus

The Investigators propose to set up a preventive trial of infection in hospital workers at risk of coronavirus infection by comparing the rate of SARS-Cov-2 infection in a population of negative SARS-Cov-2 hospital workers receiving preventively azithromycin, hydroxychloroquine or a Placebo

NCT04344379 SARS-CoV-2 Infection Drug: hydroxychloroquine Drug: azithromycin Drug: hydroxychloroquine placebo
MeSH:Infection

Primary Outcomes

Description: The number of hospital workers with a positive serology or a positive PCR within 40 days of follow-up.

Measure: To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.

Time: 3 months

Secondary Outcomes

Description: Clinical signs suggesting SARS-2 CoV infection confirmed by positive endonasal PCR

Measure: Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR

Time: 40 days

Description: number of seroconversion by serology between Day 0 and Day 40.

Measure: Reducing seroconversion for SARS-CoV-2 without any clinical sign

Time: 3 months

Description: number of cardiological severe adverse events assessed (ECG abnormalities : widening QT, ventricular arythmia, and cardiac arrests), other serious adverse events including hospitalizations, and deaths

Measure: Evaluation of drug tolerance in the study

Time: 40 days

Description: Number of work stoppages over the period

Measure: Evaluation on work stopping of hospital workers

Time: 40 days

Description: Plasmatic concentrations of treatments

Measure: Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine

Time: 40 days

Description: number of cardiac events, especialy ECG abnormalities (widening QT) due to treatments

Measure: Incidence of cardiologic events

Time: 40 days


No related HPO nodes (Using clinical trials)